S. Gardai

发表

Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms

Alexander E. Ivliev, J. Langston, G. Halliday, 2014, PloS one.

Glucocorticoids and Inhibition by Eosinophil Apoptosis: Enhancement by Oxidant-Mediated Mitochondrial Injury in

Ling-Yi L Chang, P. Henson, B. Day, 2013 .

Oxidant-Mediated Mitochondrial Injury in Eosinophil Apoptosis: Enhancement by Glucocorticoids and Inhibition by Granulocyte-Macrophage Colony-Stimulating Factor1

Ling-Yi L Chang, P. Henson, D. Bratton, 2003, The Journal of Immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha.

W. Janssen, P. Henson, D. Linderman, 2008, American journal of respiratory and critical care medicine.

By Binding SIRPα or Calreticulin/CD91, Lung Collectins Act as Dual Function Surveillance Molecules to Suppress or Enhance Inflammation

J. Nick, D. Voelker, P. Henson, 2003, Cell.

Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation.

S. Wenzel, V. Fadok, P. Henson, 2002, American journal of respiratory cell and molecular biology.

Recognition ligands on apoptotic cells: a perspective

P. Henson, D. Bratton, S. Gardai, 2006, Journal of leukocyte biology.

Apoptotic Cells, through Transforming Growth Factor-β, Coordinately Induce Anti-inflammatory and Suppress Pro-inflammatory Eicosanoid and NO Synthesis in Murine Macrophages*

W. Schiemann, P. Henson, D. Bratton, 2006, Journal of Biological Chemistry.

Activation of SHIP by NADPH Oxidase-stimulated Lyn Leads to Enhanced Apoptosis in Neutrophils*

V. Fadok, C. Helgason, P. Henson, 2002, The Journal of Biological Chemistry.

Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta.

K. Malcolm, W. Schiemann, V. Fadok, 2002, The Journal of biological chemistry.

A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors.

S. Peng, J. Drachman, Haley D Neff-Laford, 2015 .

×Phosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils*

David A Hildeman, S. K. Frankel, P. Henson, 2004, Journal of Biological Chemistry.

Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS

C. Vandevert, T. Yednock, W. Zago, 2012, PloS one.

Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte

W. Janssen, M. Michalak, P. Henson, 2005, Cell.

Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth

M. Wick, N. Voelkel, R. Nemenoff, 2003, Circulation research.

ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages

P. Linsel-Nitschke, A. Tall, W. Janssen, 2006, The Journal of cell biology.

Oxidants Inhibit ERK/MAPK and Prevent Its Ability to Delay Neutrophil Apoptosis Downstream of Mitochondrial Changes and at the Level of XIAP*

P. Henson, Peter M. Henson, Shyra J. Gardai, 2004, Journal of Biological Chemistry.

Differential Roles for αMβ2 Integrin Clustering or Activation in the Control of Apoptosis via Regulation of Akt and ERK Survival Mechanisms

V. Fadok, P. Henson, Ben B. Whitlock, 2000, The Journal of cell biology.

Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis

R. Brennan, V. Johnson, A. Olaharski, 2013, PloS one.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms

S. Alley, N. Okeley, S. Gardai, 2017 .

Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

Alexander K. Buell, Tuomas P. J. Knowles, Michele Vendruscolo, 2014, PloS one.

Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease

J. Langston, Manuel Buttini, L. McConlogue, 2013, PloS one.

Cross-talk between ERK and p38 MAPK Mediates Selective Suppression of Pro-inflammatory Cytokines by Transforming Growth Factor-β*

K. Malcolm, W. Schiemann, V. Fadok, 2002, The Journal of Biological Chemistry.

Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific

T. Comery, Manuel Buttini, P. Seubert, 2012, The Journal of Neuroscience.

TNF-α Inhibits Macrophage Clearance of Apoptotic Cells via Cytosolic Phospholipase A2 and Oxidant-Dependent Mechanisms1

W. Janssen, P. Henson, D. Bratton, 2007, The Journal of Immunology.

854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

P. Treuting, R. Boyce, Jason P. Schrum, 2021, Journal for ImmunoTherapy of Cancer.

Abstract 2742: Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor

D. Sussman, S. Gardai, Anthony T. Cao, 2018, Immunology.

Abstract 4914: Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses

C. Law, S. Gardai, Anthony T. Cao, 2016 .

Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers

P. Senter, M. Disis, D. Cecil, 2020, Molecular Cancer Therapeutics.

Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis

D. Camidge, L. Chow, H. Burris, 2018, Clinical research.

1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors

A. Nesterova, T. Lewis, Taisuke Nakazawa, 2022, Regular and Young Investigator Award Abstracts.

Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

A. Nesterova, T. Lewis, Bernard A. Liu, 2020 .

Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to β-amyloid clearance.

K. Abel, J. Cashman, M. Lanier, 2012, Chemical research in toxicology.

Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions

D. Agard, E. Masliah, G. Tóth, 2019, Scientific Reports.

250 SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement

R. Thurman, W. Zeng, S. Gardai, 2020, Journal for ImmunoTherapy of Cancer.

Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death

C. Law, S. Gardai, A. Epp, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages

P. Linsel-Nitschke, A. Tall, C. Qin, 2006, The Journal of cell biology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

P. Treuting, Jason P. Schrum, E. Trueblood, 2023, Journal for ImmunoTherapy of Cancer.

Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity

S. Gardai, S. Wo, Amber Blackmarr, 2023, Frontiers in immunology.

Abstract 1583: SEA-TGT is an empowered anti-TIGIT antibody that displays superior combinatorial activity with several therapeutic agents

S. Gardai, S. Peterson, Sasha Y. Lucas, 2021, Immunology.

618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

Bernard A. Liu, Joseph Z. Hamilton, Rebecca Mazahreh, 2020 .

Abstract 5588: Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibitionin vivo

C. Law, S. Gardai, Anthony T. Cao, 2017 .